Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology - United Kingdom
doi 10.1002/hon.126_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

High Rate of Durable Complete Remission in Follicular Lymphoma After Cd19 Car-T Cell Immunotherapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Toxicities of CD19 CAR-T Cell Immunotherapy

American Journal of Hematology
Hematology
2019English

First-Line Ibrutinib Confirmed for CLL

Cancer Discovery
Oncology
2018English

Ibrutinib May Boost Efficacy of CAR T Cells

Cancer Discovery
Oncology
2018English

Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination With Ibrutinib for Relapsed and/or Refractory CLL

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

MDS as a Cause for Prolonged Hematologic Toxicity After Treatment With Cd19 Targeted Car-T Cell Therapy in Patients With Relapsed Refractory Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy